QT Imaging Holdings, Inc. (QTI) is a medical device company that develops radiation-free breast imaging systems using low-frequency sound waves. Four current analyst targets were reviewed, producing an approximate range of $8 to $13.20 and a calculated mean of $10.05, which rounds to the $10 central target used throughout this article. This figure is a calculated average, not an officially published consensus, and it should not be read as a guarantee.
The views behind these numbers differ sharply. On the lower end, Craig-Hallum initiated coverage with an $8 target (October 2026) and D. Boral Capital initiated with $9 (October 2026). A separate reiterated target of $10 sits near the middle, while Ladenburg Thalmann has carried a notably higher $13.20 target. The spread reflects genuine uncertainty about how quickly the company can convert early commercial momentum into durable, profitable growth. Notably, a target set about a year ago can carry less informational weight than fresh initiations, which is one reason the range is so wide.
QTI has traded recently around $2.29, toward the lower end of a 52-week range of roughly $2.01 to $7.60, with a market capitalization of only about $33 million. Reaching $10 from that level would require a gain of approximately 337%, which is a very large move for a company of this size. It would effectively mean the stock more than quadruples, restoring and exceeding its prior 52-week high.
The path would depend almost entirely on execution rather than valuation re-rating alone. Revenue is growing quickly — the company reported about $14 million for the first half of 2026, up 116% year over year, and has affirmed full-year 2026 guidance of roughly $39 million — but the business is still loss-making, with trailing EPS (earnings per share) around negative $1.40. Because the company has no positive earnings to anchor a P/E (price-to-earnings) multiple, any move toward the target would have to be driven by sustained shipment growth, an expanding recurring software revenue stream, and progress toward reimbursement.
Several verified developments support a more optimistic case. QTI has secured FDA 510(k) clearances for its Breast Acoustic CT scanner, including an enhanced configuration cleared in March 2026 that improves coverage of posterior breast tissue. It has built distribution relationships with NXC Imaging (a Canon Medical Systems USA subsidiary) in the United States, Gulf Medical in Saudi Arabia, Al Naghi Medical in the UAE, and a sales agent in Pakistan. Scanner shipments have roughly doubled year over year, and the company is developing a cloud software platform intended to add recurring, higher-margin revenue.
The American Medical Association approved a Category III CPT code for the company's imaging procedure, effective January 2027 — an early but meaningful step toward a U.S. reimbursement pathway that analysts cite as central to the bull case. Additional financing and loan-maturity extensions have also improved near-term liquidity.
The obstacles are substantial. QTI remains a micro-cap with ongoing operating losses, negative free cash flow, and a reliance on equity raises and debt, which can dilute existing shareholders. U.S. reimbursement is not yet established, so domestic adoption depends on clinicians and payers embracing a new imaging modality without guaranteed coverage. Customer concentration is also a concern, since a large share of scanner revenue flows through NXC Imaging. Any slippage in shipment timing, slower international uptake, or an inability to convert the cloud platform into recurring revenue could undermine the growth assumptions embedded in the higher analyst targets.
Technically, the picture is defined by a wide trading range. The stock's 52-week low near $2.01 provides a nearby support level, while the prior 52-week high near $7.60 stands as the first major resistance level on any sustained advance. The $5 mark is a natural psychological midpoint that would have to be cleared before the stock could contemplate the $8–$13.20 target zone. Given the very thin float and low average trading volume, QTI is prone to sharp, liquidity-driven swings in both directions, which makes technical levels less reliable than they would be for a larger, more liquid name.
Analyst price targets typically reflect a research horizon of around 12 months, though individual firms may use different assumptions, and no explicit timeline was confirmed for every target reviewed here. Investors should watch quarterly scanner shipments and revenue against the roughly $39 million full-year guidance, cash burn and any new financing, the early 2027 CPT code rollout, progress on the cloud platform's recurring revenue, and new distribution or regulatory milestones. Analyst revisions following each earnings report will be the clearest signal of whether the $10 target is being reaffirmed, raised, or trimmed.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. For investors following volatile small-cap names like QTI, systematic signal tools can help filter noise from genuine trend changes.
The question of whether QTI can reach $10 is really a question about execution. The central target — the arithmetic mean of four analyst price targets spanning $8 to $13.20 — implies a gain of about 337% from recent levels, a very large move that would require the company to sustain rapid shipment growth, build recurring software revenue, and advance its reimbursement strategy. The bull case rests on real momentum: FDA clearances, expanding distribution, and more than doubling revenue. The bear case rests on persistent losses, financing needs, customer concentration, and an unproven reimbursement path. No one can guarantee the outcome, and the wide analyst range signals genuine disagreement. Investors should focus on quarterly execution, cash position, and any changes to analyst targets as the most reliable indicators of whether a move toward $10 is becoming more or less realistic.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that QTI and CSTL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that QTI and CSTL's prices will move in lockstep.
| Ticker / NAME | Correlation To QTI | 1D Price Change % | ||
|---|---|---|---|---|
| QTI | 100% | -1.31% | ||
| CSTL - QTI | 29% Poorly correlated | +0.12% | ||
| OSUR - QTI | 24% Poorly correlated | -5.67% | ||
| SENS - QTI | 23% Poorly correlated | +2.35% | ||
| CTKB - QTI | 22% Poorly correlated | -1.70% | ||
| NUWE - QTI | 22% Poorly correlated | +6.07% | ||
More | ||||
| Ticker / NAME | Correlation To QTI | 1D Price Change % |
|---|---|---|
| QTI | 100% | -1.31% |
| Medical/Nursing Services industry (138 stocks) | -1% Poorly correlated | -1.46% |
| Health Services industry (239 stocks) | -3% Poorly correlated | -1.13% |